골다공증 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 투여 경로별, 약제 유형별, 지역별, 경쟁별(2020-2030년)
Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Drug Type, By Region and Competition, 2020-2030F
상품코드:1764079
리서치사:TechSci Research
발행일:2025년 06월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 골다공증 치료제 시장은 2024년에 134억 달러로 평가되며, 2030년에는 169억 1,000만 달러에 달하며, CAGR 4.15%로 성장할 것으로 예측됩니다.
골다공증은 골량 감소와 골절 위험 증가를 특징으로 하는 진행성 골격계 질환으로, 주로 폐경기 이후 여성과 노년층에서 많이 발생합니다. 전 세계에서 평균 수명이 늘어남에 따라 골다공증과 그에 따른 골절의 유병률도 증가하여 약리요법에 대한 강력한 수요를 견인하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
134억 달러
시장 규모 : 2030년
169억 1,000만 달러
CAGR : 2025-2030년
4.15%
급성장 부문
경구
최대 시장
북미
이 시장은 비스포스포네이트, SERM, RANK 리간드 억제제, 칼시토닌, 부갑상선 호르몬 유사체 등 다양한 약물 카테고리에 걸쳐 있습니다. 알렌드로네이트와 리세드로네이트와 같은 비스포스포네이트 계열 약물은 저렴한 가격과 광범위한 임상적 사용으로 인해 역사적으로 우위를 점해왔습니다. 시장 전망은 여전히 좋지만, 새로운 생물제제 치료에 따른 높은 비용, 장기적인 부작용에 대한 우려, 순응도 문제 등 여러 가지 문제들이 여전히 광범위한 채택을 저해하고 있습니다.
The Global Osteoporosis Drugs Market was valued at USD 13.40 Billion in 2024 and is projected to reach USD 16.91 Billion by 2030, growing at a CAGR of 4.15%. Osteoporosis, a progressive skeletal disorder marked by low bone mass and heightened fracture risk, predominantly affects postmenopausal women and the elderly. As global life expectancy rises, so too does the prevalence of osteoporosis and associated fractures, driving strong demand for pharmacological therapies.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 13.40 Billion
Market Size 2030
USD 16.91 Billion
CAGR 2025-2030
4.15%
Fastest Growing Segment
Oral
Largest Market
North America
The market spans various drug categories, including bisphosphonates, SERMs, RANK ligand inhibitors, calcitonin, and parathyroid hormone analogs. Bisphosphonates, such as alendronate and risedronate, have historically dominated due to their affordability and widespread clinical use. While the market outlook remains favorable, challenges such as high costs associated with newer biologic treatments, concerns regarding long-term side effects, and adherence issues continue to temper broader adoption.
Key Market Drivers
Growth in Healthcare Industry
The global healthcare sector's continued growth plays a pivotal role in advancing the osteoporosis drugs market. With annual sales surpassing USD 4 trillion, key healthcare segments include pharmaceuticals and biotechnology, generating nearly USD 850 billion, and medical diagnostics and technology, contributing over USD 400 billion. As healthcare infrastructure expands and access improves worldwide, there is a heightened focus on early detection and effective treatment of chronic age-related conditions like osteoporosis. This rising awareness and investment are translating into increased demand for medications aimed at enhancing bone density and minimizing fracture risk.
Key Market Challenges
High Cost of Therapy
The substantial cost of osteoporosis therapy presents a major barrier to widespread access, particularly in lower-income and underinsured populations. Although biologics such as denosumab and parathyroid hormone analogs like teriparatide offer strong efficacy for high-risk patients, these treatments are priced significantly higher than conventional options like bisphosphonates. This pricing disparity limits affordability, especially in regions where public healthcare systems are underfunded or health insurance coverage is insufficient. The long-term nature of osteoporosis treatment further intensifies the economic burden for patients and providers alike.
Key Market Trends
Rise in Home-Based Osteoporosis Care
The growing shift toward home-based osteoporosis management is reshaping the landscape of care delivery. In May 2023, the International Osteoporosis Foundation (IOF) launched the Build Better Bones platform-a digital resource designed to support individuals and caregivers with practical tools for strengthening bones and preventing fragility fractures. This trend reflects a broader move toward patient-centric care models, particularly for elderly or mobility-limited patients.
By facilitating remote education, personalized exercise routines, and nutritional guidance, home-based care helps improve adherence to long-term drug regimens and enhances clinical outcomes. It also reduces pressure on healthcare facilities, offering a more accessible and cost-effective approach to chronic disease management.
Key Market Players
Eli Lilly and Company
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc.
Novartis International AG
Merck & Co. Inc.
Amgen Inc.
Radius Health Inc.
Actavis PLC
Report Scope
In this report, the Global Osteoporosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Osteoporosis Drugs Market, By Route of Administration:
Oral
Injectables
Others
Osteoporosis Drugs Market, By Drug Type:
Parathyroid Hormone Therapy
Bisphosphonates
Calcitonin
Selective Estrogen Receptor Modulators
Others
Osteoporosis Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Osteoporosis Drugs Market.
Available Customizations
Global Osteoporosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Osteoporosis Drugs Market
5. Global Osteoporosis Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Oral, Injectables, Others)
5.2.2. By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Osteoporosis Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration
6.2.2. By Drug Type
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Osteoporosis Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Drug Type
6.3.2. Mexico Osteoporosis Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Drug Type
6.3.3. Canada Osteoporosis Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Drug Type
7. Europe Osteoporosis Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration
7.2.2. By Drug Type
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Osteoporosis Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Drug Type
7.3.2. Germany Osteoporosis Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Drug Type
7.3.3. United Kingdom Osteoporosis Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Drug Type
7.3.4. Italy Osteoporosis Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Drug Type
7.3.5. Spain Osteoporosis Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Drug Type
8. Asia Pacific Osteoporosis Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration
8.2.2. By Drug Type
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Osteoporosis Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Drug Type
8.3.2. India Osteoporosis Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Drug Type
8.3.3. South Korea Osteoporosis Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Drug Type
8.3.4. Japan Osteoporosis Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Drug Type
8.3.5. Australia Osteoporosis Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Drug Type
9. South America Osteoporosis Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration
9.2.2. By Drug Type
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Osteoporosis Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Drug Type
9.3.2. Argentina Osteoporosis Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Drug Type
9.3.3. Colombia Osteoporosis Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Drug Type
10. Middle East and Africa Osteoporosis Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration
10.2.2. By Drug Type
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Osteoporosis Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Drug Type
10.3.2. Saudi Arabia Osteoporosis Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Drug Type
10.3.3. UAE Osteoporosis Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Drug Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions : Conflicts, Pandemics and Trade Barriers
14. Global Osteoporosis Drugs Market: SWOT Analysis
